Isoprinosine for Hand‑Foot‑and‑Mouth Disease (HFMD)
Bold recommendation: Isoprinosine should NOT be used as an adjunct treatment for HFMD; there is no guideline or high‑quality evidence showing morbidity, mortality, or quality‑of‑life benefit in HFMD. 1
- Evidence hierarchy and applicability
- Guidelines: No HFMD guideline endorses isoprinosine; contemporary reviews state no approved antivirals for HFMD and recommend supportive care, with IVIG only for severe/complicated cases (to reduce neurologic/cardiopulmonary complications) 1.
- Drug label: The provided “isoprinosine (PO)” entries describe a first‑aid topical antiseptic, not an oral immunomodulator; this is not applicable to systemic viral HFMD and offers no proven outcome benefit 2.
- Research:
- Animal/agricultural FMD (foot‑and‑mouth disease in livestock) vaccine adjuvant data are non‑human, disease‑mismatched, and not applicable to pediatric HFMD caused by human enteroviruses 3.
- Historic non‑HFMD antiviral signals (e.g., influenza/SSPE) are outdated, small, and not generalizable to HFMD; they do not demonstrate morbidity/mortality/QoL benefit in HFMD 4, 5.
- The most recent clinical HFMD RCT signals benefit for EPs 7630 (Pelargonium sidoides), not isoprinosine; while promising for symptom duration and hospitalization, it does not validate isoprinosine use 6.
What to do instead (prioritizing morbidity, mortality, QoL)
- Uncomplicated HFMD
- Supportive care: antipyretics/analgesics, hydration, topical oral analgesia for painful ulcers. No antivirals recommended 1.
- Severe/complicated HFMD (red flags: lethargy, irritability, myoclonus, ataxia, bulbar/brainstem signs, persistent vomiting, tachycardia, hypertension, pulmonary edema, cardiorespiratory instability)
- Escalate to hospital care; consider IVIG per national/consensus recommendations to reduce neurologic/cardiopulmonary complications 1.
- Avoid pitfalls